International uniform response criteria for multiple myeloma

B. G.M. Durie; J. L. Harousseau; J. S. Miguel; J. Bladé; B. Barlogie; K. Anderson; M. Gertz; M. Dimopoulos; J. Westin; P. Sonneveld; H. Ludwig; G. Gahrton; M. Beksac; J. Crowley; A. Belch; M. Boccadaro; M. Cavo; I. Turesson; D. Joshua; D. Vesole; R. Kyle; G. Tricot; R. Alexanian; M. Attal; G. Merlini; R. Powles; P. Richardson; K. Shimizu; P. Tosi; S. V. Rajkumar; G. Morgan

doi:10.1038/sj.leu.2404284

International uniform response criteria for multiple myeloma

B. G.M. Durie
, J. L. Harousseau
, J. S. Miguel
, J. Bladé
, B. Barlogie
, K. Anderson
, M. Gertz
, M. Dimopoulos
, J. Westin
, P. Sonneveld
, H. Ludwig
, G. Gahrton
, M. Beksac
, J. Crowley
, A. Belch
, M. Boccadaro
, M. Cavo
, I. Turesson
, D. Joshua
, D. Vesole

R. Kyle, G. Tricot, R. Alexanian, M. Attal, G. Merlini, R. Powles, P. Richardson, K. Shimizu, P. Tosi, S. V. Rajkumar, G. Morgan

School of Medicine

Aptium Oncology, Inc.
Institut national de la santé et de la recherche médicale
Universidad de Salamanca
University Hospital Clinic
University of Arkansas for Medical Sciences
DFCI
Mayo Clinic Rochester, MN
Alexandra Hospital
Lund University
Klinik Ottakring
Karolinska Institutet
Ankara University
Fred Hutchinson Cancer Research Center
Cross Cancer Institute
University of Turin
University of Bologna
Malmö University
Royal Prince Alfred Hospital
University of Texas MD Anderson Cancer Center
CHU de Toulouse
University of Pavia
The Leukemia and Myeloma Program
Dana-Farber Cancer Institute
Nagoya City Midori General Hospital
Royal Marsden NHS Foundation Trust

Research output: Contribution to journal › Article › peer-review

2510 Scopus citations

Abstract

New uniform response criteria are required to adequately assess clinicaloutcomes in myeloma. The European Group for Blood and Bone MarrowTransplant/International Bone Marrow Transplant Registry criteria have beenexpanded, clarified and updated to provide a new comprehensive evaluationsystem. Categories for stringent complete response and very good partialresponse are added. The serum free light-chain assay is included to allowevaluation of patients with oligo-secretory disease. Inconsistencies in priorcriteria are clarified making confirmation of response and disease progressioneasier to perform. Emphasis is placed upon time to event and duration ofresponse as critical end points. The requirements necessary to use overallsurvival duration as the ultimate end point are discussed. It is anticipatedthat the International Response Criteria for multiple myeloma will be widelyused in future clinical trials of myeloma.

Original language	English
Pages (from-to)	1467-1473
Number of pages	7
Journal	Leukemia
Volume	20
Issue number	9
DOIs	https://doi.org/10.1038/sj.leu.2404284
State	Published - 1 Sep 2006

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Clinical outcomes
Myeloma
Response criteria
Staging
Survival duration
Uniform criteria

Access to Document

10.1038/sj.leu.2404284

Cite this

Durie, B. G. M., Harousseau, J. L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., ... Morgan, G. (2006). International uniform response criteria for multiple myeloma. Leukemia, 20(9), 1467-1473. https://doi.org/10.1038/sj.leu.2404284

@article{91198fa8b81b4a0fb1657c325f057af9,

title = "International uniform response criteria for multiple myeloma",

abstract = "New uniform response criteria are required to adequately assess clinicaloutcomes in myeloma. The European Group for Blood and Bone MarrowTransplant/International Bone Marrow Transplant Registry criteria have beenexpanded, clarified and updated to provide a new comprehensive evaluationsystem. Categories for stringent complete response and very good partialresponse are added. The serum free light-chain assay is included to allowevaluation of patients with oligo-secretory disease. Inconsistencies in priorcriteria are clarified making confirmation of response and disease progressioneasier to perform. Emphasis is placed upon time to event and duration ofresponse as critical end points. The requirements necessary to use overallsurvival duration as the ultimate end point are discussed. It is anticipatedthat the International Response Criteria for multiple myeloma will be widelyused in future clinical trials of myeloma.",

keywords = "Clinical outcomes, Myeloma, Response criteria, Staging, Survival duration, Uniform criteria",

author = "Durie, \{B. G.M.\} and Harousseau, \{J. L.\} and Miguel, \{J. S.\} and J. Blad{\'e} and B. Barlogie and K. Anderson and M. Gertz and M. Dimopoulos and J. Westin and P. Sonneveld and H. Ludwig and G. Gahrton and M. Beksac and J. Crowley and A. Belch and M. Boccadaro and M. Cavo and I. Turesson and D. Joshua and D. Vesole and R. Kyle and G. Tricot and R. Alexanian and M. Attal and G. Merlini and R. Powles and P. Richardson and K. Shimizu and P. Tosi and Rajkumar, \{S. V.\} and G. Morgan",

year = "2006",

month = sep,

day = "1",

doi = "10.1038/sj.leu.2404284",

language = "English",

volume = "20",

pages = "1467--1473",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "9",

}

Durie, BGM, Harousseau, JL, Miguel, JS, Bladé, J, Barlogie, B, Anderson, K, Gertz, M, Dimopoulos, M, Westin, J, Sonneveld, P, Ludwig, H, Gahrton, G, Beksac, M, Crowley, J, Belch, A, Boccadaro, M, Cavo, M, Turesson, I, Joshua, D, Vesole, D, Kyle, R, Tricot, G, Alexanian, R, Attal, M, Merlini, G, Powles, R, Richardson, P, Shimizu, K, Tosi, P, Rajkumar, SV & Morgan, G 2006, 'International uniform response criteria for multiple myeloma', Leukemia, vol. 20, no. 9, pp. 1467-1473. https://doi.org/10.1038/sj.leu.2404284

TY - JOUR

T1 - International uniform response criteria for multiple myeloma

AU - Durie, B. G.M.

AU - Harousseau, J. L.

AU - Miguel, J. S.

AU - Bladé, J.

AU - Barlogie, B.

AU - Anderson, K.

AU - Gertz, M.

AU - Dimopoulos, M.

AU - Westin, J.

AU - Sonneveld, P.

AU - Ludwig, H.

AU - Gahrton, G.

AU - Beksac, M.

AU - Crowley, J.

AU - Belch, A.

AU - Boccadaro, M.

AU - Cavo, M.

AU - Turesson, I.

AU - Joshua, D.

AU - Vesole, D.

AU - Kyle, R.

AU - Tricot, G.

AU - Alexanian, R.

AU - Attal, M.

AU - Merlini, G.

AU - Powles, R.

AU - Richardson, P.

AU - Shimizu, K.

AU - Tosi, P.

AU - Rajkumar, S. V.

AU - Morgan, G.

PY - 2006/9/1

Y1 - 2006/9/1

N2 - New uniform response criteria are required to adequately assess clinicaloutcomes in myeloma. The European Group for Blood and Bone MarrowTransplant/International Bone Marrow Transplant Registry criteria have beenexpanded, clarified and updated to provide a new comprehensive evaluationsystem. Categories for stringent complete response and very good partialresponse are added. The serum free light-chain assay is included to allowevaluation of patients with oligo-secretory disease. Inconsistencies in priorcriteria are clarified making confirmation of response and disease progressioneasier to perform. Emphasis is placed upon time to event and duration ofresponse as critical end points. The requirements necessary to use overallsurvival duration as the ultimate end point are discussed. It is anticipatedthat the International Response Criteria for multiple myeloma will be widelyused in future clinical trials of myeloma.

AB - New uniform response criteria are required to adequately assess clinicaloutcomes in myeloma. The European Group for Blood and Bone MarrowTransplant/International Bone Marrow Transplant Registry criteria have beenexpanded, clarified and updated to provide a new comprehensive evaluationsystem. Categories for stringent complete response and very good partialresponse are added. The serum free light-chain assay is included to allowevaluation of patients with oligo-secretory disease. Inconsistencies in priorcriteria are clarified making confirmation of response and disease progressioneasier to perform. Emphasis is placed upon time to event and duration ofresponse as critical end points. The requirements necessary to use overallsurvival duration as the ultimate end point are discussed. It is anticipatedthat the International Response Criteria for multiple myeloma will be widelyused in future clinical trials of myeloma.

KW - Clinical outcomes

KW - Myeloma

KW - Response criteria

KW - Staging

KW - Survival duration

KW - Uniform criteria

UR - https://www.scopus.com/pages/publications/84988241358

U2 - 10.1038/sj.leu.2404284

DO - 10.1038/sj.leu.2404284

M3 - Article

C2 - 16855634

AN - SCOPUS:84988241358

SN - 0887-6924

VL - 20

SP - 1467

EP - 1473

JO - Leukemia

JF - Leukemia

IS - 9

ER -

International uniform response criteria for multiple myeloma

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this